Your browser is no longer supported. Please, upgrade your browser.
Settings
FATE Fate Therapeutics, Inc. daily Stock Chart
FATE [NASD]
Fate Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.23 Insider Own1.00% Shs Outstand68.00M Perf Week10.35%
Market Cap1.25B Forward P/E- EPS next Y-1.21 Insider Trans-62.67% Shs Float63.73M Perf Month15.11%
Income-72.20M PEG- EPS next Q-0.30 Inst Own98.00% Short Float15.03% Perf Quarter27.88%
Sales6.30M P/S199.03 EPS this Y-15.80% Inst Trans2.16% Short Ratio13.45 Perf Half Y44.97%
Book/sh2.25 P/B8.20 EPS next Y3.30% ROA-39.20% Target Price21.00 Perf Year76.63%
Cash/sh2.69 P/C6.85 EPS next 5Y- ROE-54.30% 52W Range8.64 - 20.04 Perf YTD43.73%
Dividend- P/FCF- EPS past 5Y-1.70% ROI-38.30% 52W High-7.98% Beta1.87
Dividend %- Quick Ratio6.40 Sales past 5Y37.30% Gross Margin- 52W Low113.43% ATR1.06
Employees104 Current Ratio6.40 Sales Q/Q160.00% Oper. Margin- RSI (14)56.17 Volatility7.11% 6.19%
OptionableYes Debt/Eq0.10 EPS Q/Q-13.60% Profit Margin- Rel Volume0.78 Prev Close18.74
ShortableYes LT Debt/Eq0.08 EarningsMay 07 AMC Payout- Avg Volume712.40K Price18.44
Recom1.50 SMA206.78% SMA507.00% SMA20025.39% Volume557,818 Change-1.60%
Mar-28-19Initiated SVB Leerink Outperform $20
Jan-03-19Downgrade Stephens Overweight → Equal-Weight
Nov-05-18Initiated Jefferies Buy
Aug-01-18Initiated Citigroup Buy $20
Mar-06-18Downgrade H.C. Wainwright Buy → Neutral $12
Dec-18-17Initiated Piper Jaffray Overweight $10
Oct-12-17Resumed H.C. Wainwright Buy $7
Sep-08-17Resumed Leerink Partners Outperform $7
Nov-08-16Reiterated Wedbush Outperform $8 → $7
Sep-22-16Initiated ROTH Capital Buy $8
Jul-28-16Resumed H.C. Wainwright Buy $9
Dec-04-15Initiated Wells Fargo Outperform
Oct-06-15Initiated Raymond James Outperform $8
Jun-01-15Initiated Leerink Partners Outperform $10
May-11-15Reiterated H.C. Wainwright Buy $9 → $11
Sep-08-14Initiated H.C. Wainwright Buy $9
Oct-28-13Initiated Cowen Outperform
May-08-19 01:11AM  Edited Transcript of FATE earnings conference call or presentation 7-May-19 9:00pm GMT Thomson Reuters StreetEvents
May-07-19 10:41PM  Fate Therapeutics, Inc. (FATE) Q1 2019 Earnings Call Transcript Motley Fool -5.19%
06:15PM  Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates Zacks
05:07PM  Fate Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Fate Therapeutics Reports First Quarter 2019 Financial Results and Highlights Operational Progress GlobeNewswire
May-03-19 11:23AM  Is Fate Therapeutics Inc (FATE) A Good Stock To Buy? Insider Monkey
Apr-30-19 04:05PM  Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2019 Financial Results GlobeNewswire
Apr-24-19 08:00AM  Fate Therapeutics Announces Five Presentations at the American Society of Gene & Cell Therapy 22nd Annual Meeting GlobeNewswire
Apr-18-19 08:01AM  Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development GlobeNewswire
Apr-02-19 08:00AM  Fate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment GlobeNewswire
Apr-01-19 08:01AM  Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting GlobeNewswire
Mar-26-19 12:12PM  What Do Analysts Think About Fate Therapeutics, Inc.s (NASDAQ:FATE) Earnings Trajectory? Simply Wall St. +5.39%
Mar-18-19 08:00AM  Fate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors GlobeNewswire
Mar-11-19 02:05PM  Edited Transcript of FATE earnings conference call or presentation 5-Mar-19 10:00pm GMT Thomson Reuters StreetEvents
Mar-06-19 01:19AM  Fate Therapeutics Inc (FATE) Q4 2018 Earnings Conference Call Transcript Motley Fool
Mar-05-19 04:01PM  Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress GlobeNewswire
03:00PM  Fate Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-28-19 04:43PM  Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
10:43AM  Cronos (CRON) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-25-19 10:30AM  Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks +12.83%
07:30AM  Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx N.V, Enerplus, and ManTech International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-22-19 08:00AM  Fate Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-20-19 08:00AM  Fate Therapeutics Appoints Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation GlobeNewswire
Feb-07-19 04:01PM  Fate Therapeutics to Present at Guggenheim Healthcare Talks Idea Forum Oncology Day GlobeNewswire -6.06%
Feb-06-19 08:37AM  Fate Therapeutics stock up 11% after FDA clears IND application MarketWatch
08:00AM  Fate Therapeutics Announces FDA Clearance of IND Application for Worlds First Cell Therapy Derived from an Engineered Pluripotent Stem Cell GlobeNewswire
Jan-22-19 11:52AM  Why Fate Therapeutics, Inc.s (NASDAQ:FATE) CEO Pay Matters To You Simply Wall St. -7.36%
Dec-19-18 12:04AM  Fate Therapeutics Inc (FATE) Hedge Funds Are Snapping Up Insider Monkey -6.05%
Dec-04-18 09:11AM  Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting GlobeNewswire
Dec-03-18 04:01PM  Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products GlobeNewswire +10.48%
08:44AM  Fate Therapeutics (FATE) Jumps: Stock Rises 8.9% Zacks
07:40AM  Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences Discovering Underlying Factors of Influence GlobeNewswire
Nov-30-18 09:30AM  How Healthcare Is Evolving & Sector Stocks To Watch ACCESSWIRE +8.94%
09:10AM  Shares of Fate Therapeutics up 4.1% in premarket trade after FDA accepts IND application for potential cancer treatment MarketWatch
08:00AM  Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy GlobeNewswire
Nov-28-18 04:22PM  3 Themes To Watch As Biopharmas 'Bring Some Excitement' In Blood Cancer Investor's Business Daily
Nov-16-18 10:35AM  What Kind Of Shareholder Appears On The Fate Therapeutics Incs (NASDAQ:FATE) Shareholder Register? Simply Wall St.
Nov-11-18 05:42PM  Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500 GlobeNewswire
Nov-08-18 04:01PM  Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire -10.00%
Nov-07-18 01:15AM  Edited Transcript of FATE earnings conference call or presentation 1-Nov-18 9:00pm GMT Thomson Reuters StreetEvents
Nov-01-18 06:40PM  Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates Zacks +9.23%
05:35PM  Fate Therapeutics: 3Q Earnings Snapshot Associated Press
04:01PM  Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress GlobeNewswire
09:01AM  Fate Therapeutics Announces Seven Presentations at the 2018 ASH Annual Meeting GlobeNewswire
Oct-29-18 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2018 Financial Results GlobeNewswire -7.30%
Oct-25-18 03:55PM  3 Healthcare Stocks To Watch On Thursday ACCESSWIRE +17.68%
Oct-24-18 09:10AM  New Research: Key Drivers of Growth for Workhorse Group, Fate Therapeutics, Minerals Technologies, Tyson Foods, ZAGG, and USA Technologies Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -9.89%
Oct-04-18 08:00AM  Fate Therapeutics Appoints Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations GlobeNewswire
Oct-03-18 07:00AM  This Biotech Stock Has Quadrupled and Its Top Shareholder Is Still Buying Barrons.com
Sep-25-18 04:01PM  Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
08:00AM  Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-20-18 11:37PM  Fate Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire +5.01%
04:11PM  Fate Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
01:32PM  Why You Need To Look At This Factor Before Buying Fate Therapeutics Inc (NASDAQ:FATE) Simply Wall St.
Sep-17-18 07:00PM  Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies GlobeNewswire
Sep-13-18 08:00AM  Fate Therapeutics Enters into Exclusive License Agreement with Gladstone Institutes for CRISPR-based Cellular Reprogramming GlobeNewswire
Sep-11-18 02:12PM  Edited Transcript of FATE earnings conference call or presentation 6-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Aug-31-18 08:10AM  Research Report Identifies Kronos Worldwide, The Gap, Citigroup, Cadence Design, SPX FLOW, and Fate Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-29-18 04:01PM  Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-07-18 04:01PM  Fate Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire +11.21%
Aug-06-18 06:00PM  Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:58PM  Fate Therapeutics: 2Q Earnings Snapshot Associated Press
04:01PM  Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress GlobeNewswire
03:00PM  Fate Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
08:39AM  Fate Therapeutics Q2 Earnings Preview Benzinga
Jul-30-18 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2018 Financial Results GlobeNewswire
Jul-27-18 07:35AM  Recent Analysis Shows Synopsys, Rigel Pharmaceuticals, Fate Therapeutics, Philip Morris International, Sally Beauty, and Kimberly-Clark Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jul-26-18 10:59AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Fate Therapeutics, Inc. -- FATE GlobeNewswire
06:57AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Fate Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Jul-10-18 07:45AM  Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks ACCESSWIRE
Jun-21-18 09:48AM  3 Sectors to Buy in a Trade War Investopedia
Jun-01-18 04:01PM  Fate Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-22-18 07:40AM  Analysis: Positioning to Benefit within Beazer Homes, Tejon Ranch, Ladder Capital, Fate Therapeutics, Benefitfocus, and H&E Equipment Services Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-16-18 08:00AM  Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies GlobeNewswire +5.06%
May-10-18 11:46PM  Edited Transcript of FATE earnings conference call or presentation 10-May-18 9:00pm GMT Thomson Reuters StreetEvents
04:07PM  Fate Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress GlobeNewswire
May-03-18 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2018 Financial Results GlobeNewswire
May-02-18 08:00AM  Fate Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire
Apr-16-18 09:30AM  Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual Meeting Press Program GlobeNewswire
Apr-10-18 03:03PM  Fate Therapeutics Incs (NASDAQ:FATE) Shift From Loss To Profit Simply Wall St. +6.12%
Apr-03-18 07:05AM  Wired News - Fate Therapeutics Presented Positive Clinical Data of FATE-NK100's APOLLO Phase-1 Study in Recurrent Ovarian Cancer at the Innate Killer Summit 2018 ACCESSWIRE
Mar-30-18 01:31PM  Edited Transcript of FATE earnings conference call or presentation 1-Nov-17 9:00pm GMT Thomson Reuters StreetEvents
Mar-29-18 08:00AM  Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018 GlobeNewswire
Mar-28-18 07:45AM  Recent Analysis Shows EPAM, Sibanye Gold, Fate Therapeutics, Howard Hughes, CBL & Associates Properties, and Quorum Health Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire -6.84%
Mar-27-18 10:43AM  Edited Transcript of FATE earnings conference call or presentation 5-Mar-18 10:00pm GMT Thomson Reuters StreetEvents -11.50%
Mar-19-18 08:00AM  Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune GlobeNewswire
Mar-13-18 07:40AM  Wired News CTI BioPharmas Pacritinib Phase-3 PERSIST-2 Clinical Trial Data Published in JAMA Oncology ACCESSWIRE -7.58%
Mar-05-18 04:15PM  Fate Therapeutics reports 4Q loss Associated Press
04:01PM  Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress GlobeNewswire
Feb-27-18 08:00AM  Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Feb-24-18 10:37AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Feb-23-18 08:00AM  Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy GlobeNewswire +11.15%
Feb-20-18 08:00AM  Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors GlobeNewswire
Feb-12-18 04:01PM  Fate Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Feb-05-18 03:49PM  With A -16.46% Earnings Drop, Is Fate Therapeutics Incs (NASDAQ:FATE) Performance A Concern? Simply Wall St. -9.71%
Jan-25-18 08:25AM  Research Report Identifies Fate Therapeutics, A. Schulman, Celadon Group, Egalet, Meredith, and HCP with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jan-23-18 12:09PM  Here's Why Fate Therapeutics Rose as Much as 18% Today Motley Fool +10.01%
Jan-18-18 06:27PM  3 Stocks Under $10 That Surged Today Zacks
Dec-30-17 10:37AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy comprising adaptive memory NK cells; FT500, an induced pluripotent stem cell (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516, an iPSC-derived non-cleavable CD16 engineered NK cell product candidate to treat hematologic malignancies and solid tumors; and FT596, a chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies. The company's immuno-oncology product candidates also include FT538, an NK cell product candidate for treating multiple myeloma; and FT819, a CAR T-cell product candidate for the treatment of liquid and solid tumors. Its immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and FT301, an immuno-regulatory cell product candidate for various disease indications, including graft-versus-host disease, multiple sclerosis, ulcerative colitis, and others. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wolchko J ScottPresident and CEOMay 16Option Exercise1.6314,33523,366389,216May 17 06:27 PM
Wolchko J ScottPresident and CEOMay 16Sale19.3714,335277,684374,881May 17 06:27 PM
Wolchko J ScottPresident and CEOApr 18Option Exercise1.6311,45918,678381,724Apr 19 04:13 PM
Wolchko J ScottPresident and CEOApr 18Sale16.0111,459183,509374,881Apr 19 04:13 PM
Wolchko J ScottPresident and CEOApr 17Option Exercise1.638,54113,922382,330Apr 19 04:13 PM
Wolchko J ScottPresident and CEOApr 17Sale16.178,541138,132374,881Apr 19 04:13 PM
Shoemaker Daniel DChief Scientific OfficerMar 28Option Exercise2.9012,50036,250148,091Mar 29 04:01 PM
Shoemaker Daniel DChief Scientific OfficerMar 28Sale16.9412,500211,703135,591Mar 29 04:01 PM
Wolchko J ScottPresident and CEOMar 21Option Exercise1.6320,00032,600394,881Mar 22 04:01 PM
Wolchko J ScottPresident and CEOMar 21Sale17.6120,000352,160374,881Mar 22 04:01 PM
TAHL CINDYGeneral Counsel and SecretaryMar 01Option Exercise2.9025,00072,500115,418Mar 05 09:00 AM
TAHL CINDYGeneral Counsel and SecretaryMar 01Sale16.1525,000403,69890,418Mar 05 09:00 AM
TAHL CINDYGeneral Counsel and SecretaryFeb 25Option Exercise2.9025,00072,500115,418Feb 27 04:01 PM
TAHL CINDYGeneral Counsel and SecretaryFeb 25Sale16.0725,000401,82090,418Feb 27 04:01 PM
Nashat AmirDirectorJan 30Sale14.1653,017750,9591,473,186Feb 01 05:02 PM
Nashat AmirDirectorJan 29Sale14.1697,5001,380,7951,526,203Jan 31 06:00 PM
Nashat AmirDirectorJan 28Sale13.7870,000964,7681,623,703Jan 30 04:10 PM
Nashat AmirDirectorJan 25Sale14.1490,0001,272,7531,693,703Jan 29 04:31 PM
Nashat AmirDirectorJan 18Sale16.2839,483642,8341,783,703Jan 23 04:32 PM
TAHL CINDYGeneral Counsel and SecretaryJan 07Option Exercise2.2725,00056,67370,418Jan 09 04:03 PM
TAHL CINDYGeneral Counsel and SecretaryJan 07Sale16.0025,000400,00045,418Jan 09 04:03 PM
Nashat AmirDirectorDec 20Sale12.2533,474410,1601,823,186Dec 26 04:13 PM
Nashat AmirDirectorDec 19Sale13.4091,2101,222,5921,856,660Dec 21 04:12 PM
Nashat AmirDirectorDec 13Sale16.6717,788296,5631,947,870Dec 17 04:25 PM
Nashat AmirDirectorDec 12Sale16.78425,0007,132,6901,965,658Dec 14 04:33 PM
Nashat AmirDirectorDec 11Sale16.7182,5281,379,1832,390,658Dec 13 05:14 PM
Redmile Group, LLCDirectorSep 25Buy13.503,703,70450,000,00410,359,666Sep 27 04:23 PM